Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Symbol: CMMB
Exchange: Nasdaq
Sector: Healthcare
Industry: Biotechnology
Market cap: $10.28M
52 week range: 1.05 - 3.58

Valuation

Share price: $1.43 (close of 2026-10-02)

Price performance

Period	Change
1 day	+10.00%
5 days	-33.80%
1 month	-47.62%
3 months	-37.00%
6 months	-8.33%
Year to date	-13.33%
1 year	-47.04%
3 years	-59.83%
5 years	-96.69%
All time	-99.79%

Profitability and growth

Return on equity: -72.93%
Return on invested capital: -5791.11%
Return on assets: -65.12%
Return on capital employed: -908.06%
Net income growth: 35.50%
Free cash flow growth: 27.64%

Cash flow and balance sheet

Current ratio: 9.08x
Net debt to EBITDA: 1.10x

Latest reported year

Period end: 2025-12-31
Fiscal year: 2025
EBITDA: -$111.93M
Net income: -$8.99M
Research and development: $5.83M

Income statement by year

Period end	Net income
2025-12-31	-$8.99M
2024-12-31	-$13.95M
2023-12-31	-$24.22M
2022-12-31	-$27.65M
2021-12-31	-$12.48M
2020-12-31	-$5.95M
2019-12-31	-$27.12M
2018-12-31	-$13.80M
2017-12-31	-$9.81M
2016-12-31	-$4.74M

Margins and returns by year

Period end	Return on equity	Return on capital
2025-12-31	-72.93%	-5791.11%
2024-12-31	-103.01%	-
2023-12-31	-142.50%	-
2022-12-31	-76.32%	-
2021-12-31	-20.30%	-
2020-12-31	-55.09%	-
2019-12-31	-219.22%	-
2018-12-31	1265.87%	-
2017-12-31	1610.18%	-
2016-12-31	-143.87%	-

Cash and debt by year

Period end	Cash
2025-12-31	$10.40M
2024-12-31	$14.30M
2023-12-31	$9.29M
2022-12-31	$13.52M
2021-12-31	$15.19M
2020-12-31	$11.67M
2019-12-31	$17.57M
2018-12-31	$7.52M
2017-12-31	$1.45M

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	-$11.13M	$623.00K
2024-12-31	-$15.39M	$617.00K
2023-12-31	-$23.61M	$1.49M
2022-12-31	-$20.44M	$3.21M
2021-12-31	-$12.61M	$2.02M
2020-12-31	-$5.28M	$130.00K
2019-12-31	-$16.55M	$1.16M
2018-12-31	-$14.44M	$1.93M
2017-12-31	-$8.55M	$730.00K
2016-12-31	-$3.81M	$270.00K

Investor relations

Next earnings report

Next confirmed report: 2026-10-08

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-10-01	Sep/2026	-
2026-09-24	Sep/2026	-
2026-09-10	Sep/2026	-
2026-09-03	Sep/2026	-
2026-08-27	Sep/2026	-
2026-08-20	Sep/2026	-
2026-08-13	Jun/2026	-
2026-05-14	Mar/2026	-

Filings and sources

Company website: chemomab.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Moderna, Inc. (MRNA) · Regeneron Pharmaceuticals, Inc. (REGN) · Insmed Inc (INSM) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades